JP2023029988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023029988A5 JP2023029988A5 JP2022196214A JP2022196214A JP2023029988A5 JP 2023029988 A5 JP2023029988 A5 JP 2023029988A5 JP 2022196214 A JP2022196214 A JP 2022196214A JP 2022196214 A JP2022196214 A JP 2022196214A JP 2023029988 A5 JP2023029988 A5 JP 2023029988A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- binding site
- chain variable
- antigen binding
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457780P | 2017-02-10 | 2017-02-10 | |
| US62/457,780 | 2017-02-10 | ||
| PCT/US2018/017653 WO2018148566A1 (en) | 2017-02-10 | 2018-02-09 | Proteins binding bcma, nkg2d and cd16 |
| JP2019543761A JP7257323B2 (ja) | 2017-02-10 | 2018-02-09 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543761A Division JP7257323B2 (ja) | 2017-02-10 | 2018-02-09 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023029988A JP2023029988A (ja) | 2023-03-07 |
| JP2023029988A5 true JP2023029988A5 (https=) | 2023-06-29 |
Family
ID=63107848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543761A Active JP7257323B2 (ja) | 2017-02-10 | 2018-02-09 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2022196214A Pending JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543761A Active JP7257323B2 (ja) | 2017-02-10 | 2018-02-09 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190375838A1 (https=) |
| EP (1) | EP3579876A4 (https=) |
| JP (2) | JP7257323B2 (https=) |
| KR (2) | KR20240078657A (https=) |
| CN (1) | CN110461361A (https=) |
| AU (1) | AU2018219348A1 (https=) |
| BR (1) | BR112019016424A2 (https=) |
| CA (1) | CA3054642A1 (https=) |
| IL (1) | IL268567A (https=) |
| MA (1) | MA47465A (https=) |
| MX (1) | MX2019009566A (https=) |
| MY (1) | MY205850A (https=) |
| SG (1) | SG11201907253VA (https=) |
| WO (1) | WO2018148566A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015158671A1 (en) * | 2014-04-14 | 2015-10-22 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| MA47465A (fr) * | 2017-02-10 | 2019-12-18 | Dragonfly Therapeutics Inc | Protéines fixant le bcma, le nkg2d et le cd16 |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| AU2018322178A1 (en) * | 2017-08-23 | 2020-02-20 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| WO2020033630A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| KR20220024106A (ko) * | 2019-05-20 | 2022-03-03 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| AR122546A1 (es) | 2020-06-05 | 2022-09-21 | Eisai R&D Man Co Ltd | Conjugados de anticuerpo anti bcma-fármaco y métodos de uso |
| CN112029001B (zh) * | 2020-09-02 | 2022-09-06 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
| JP2023545099A (ja) * | 2020-10-08 | 2023-10-26 | アフィメド ゲーエムベーハー | 三重特異性バインダー |
| US20240174768A1 (en) | 2021-03-03 | 2024-05-30 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Bispecific antibodies enhancing cell mediated immune responses |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| IL307312A (en) * | 2021-03-31 | 2023-11-01 | Janssen Biotech Inc | Materials and methods for redirecting immune effector cells |
| WO2024020577A2 (en) * | 2022-07-22 | 2024-01-25 | Fred Hutchinson Cancer Center | Antibodies against sars-cov-2 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909832A4 (en) * | 2005-06-29 | 2010-01-13 | Univ Miami | ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY |
| WO2007146968A2 (en) * | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| ES2563027T3 (es) * | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| EP2306234A3 (de) * | 2009-10-02 | 2011-06-22 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Optischer Aliasfilter, Pixelsensoranordnung und digitale Aufnahmevorrichtung |
| US9683052B2 (en) * | 2011-03-25 | 2017-06-20 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP3795215A1 (en) * | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| MX354862B (es) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes. |
| JP6636803B2 (ja) * | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| US20140323315A1 (en) * | 2013-04-29 | 2014-10-30 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| WO2015197582A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| TWI750110B (zh) * | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| CN107530424A (zh) * | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| RS61907B1 (sr) * | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| SG11201907299XA (en) * | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| WO2018148447A1 (en) * | 2017-02-08 | 2018-08-16 | Adimab, Llc | Antibody heavy chain variable domains targeting the nkg2d receptor |
| MA47465A (fr) * | 2017-02-10 | 2019-12-18 | Dragonfly Therapeutics Inc | Protéines fixant le bcma, le nkg2d et le cd16 |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
-
2018
- 2018-02-09 MA MA047465A patent/MA47465A/fr unknown
- 2018-02-09 AU AU2018219348A patent/AU2018219348A1/en not_active Abandoned
- 2018-02-09 KR KR1020247004861A patent/KR20240078657A/ko not_active Ceased
- 2018-02-09 WO PCT/US2018/017653 patent/WO2018148566A1/en not_active Ceased
- 2018-02-09 KR KR1020197026174A patent/KR20190115469A/ko not_active Ceased
- 2018-02-09 CN CN201880021558.4A patent/CN110461361A/zh active Pending
- 2018-02-09 US US16/484,936 patent/US20190375838A1/en active Pending
- 2018-02-09 JP JP2019543761A patent/JP7257323B2/ja active Active
- 2018-02-09 EP EP18750616.7A patent/EP3579876A4/en active Pending
- 2018-02-09 CA CA3054642A patent/CA3054642A1/en active Pending
- 2018-02-09 SG SG11201907253VA patent/SG11201907253VA/en unknown
- 2018-02-09 MX MX2019009566A patent/MX2019009566A/es unknown
- 2018-02-09 BR BR112019016424A patent/BR112019016424A2/pt not_active Application Discontinuation
- 2018-02-09 MY MYPI2019004552A patent/MY205850A/en unknown
-
2019
- 2019-08-07 IL IL268567A patent/IL268567A/en unknown
-
2022
- 2022-12-08 JP JP2022196214A patent/JP2023029988A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023029988A5 (https=) | ||
| JP2025109759A5 (https=) | ||
| JP2020507328A5 (https=) | ||
| US5945311A (en) | Method for producing heterologous bi-specific antibodies | |
| Krah et al. | Engineering bispecific antibodies with defined chain pairing | |
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 | |
| IL261674A (en) | Protein-like binding proteins with a double variable region have a cross-linking region direction | |
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JPWO2020077276A5 (https=) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2018526981A5 (https=) | ||
| FI3392276T3 (fi) | Heterodimeerimolekyyli, joka perustuu rakenteelliseen CH3-domeeniin, sekä menetelmä sen valmistamiseksi ja sen käyttö | |
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| HRP20200382T1 (hr) | Humanizirana ili kimerna protutijela cd3 | |
| JPWO2020076970A5 (https=) | ||
| WO2008122886A2 (en) | Transgenic non-human mammal with homodimeric vh binding complex | |
| RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
| IL311617A (en) | NKG2D, CD16 and BAFF-R binding proteins | |
| JP2025160226A5 (https=) | ||
| Spasevska | An outlook on bispecific antibodies: Methods of production and therapeutic benefits | |
| JPWO2022102768A5 (https=) | ||
| JPWO2020033664A5 (https=) | ||
| JPWO2021222578A5 (https=) | ||
| JPWO2021030680A5 (https=) | ||
| JP2025118753A5 (https=) |